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Abstract
Background: Childhood obesity and overweight affect approximately 30% of US children. Many of these children have obesity-related
comorbidities, such as hypertension, dyslipidemia, fatty liver disease, diabetes, polycystic ovary syndrome (PCOS), sleep apnea, psy-
chosocial problems, and others. These children need routine screening and, in many cases, treatment for these conditions. However,
because primary care pediatric providers (PCPs) often are underequipped to deal with these comorbidities, they frequently refer these
patients to subspecialists. However, as a result of the US pediatric subspecialist shortage and considering that 12.5 million children are
obese, access to care by subspecialists is limited. The aim of this article is to provide accessible, user-friendly clinical consensus statements
to facilitate the screening, interpretation of results, and early treatment for some of the most common childhood obesity comorbidities.
Methods: Members of the Children’s Hospital Association (formerly NACHRI) FOCUS on a Fitter Future II (FFFII), a collab-
oration of 25 US pediatric obesity centers, used a combination of the best available evidence and collective clinical experience to
develop consensus statements for pediatric obesity-related comorbidities. FFFII also surveyed the participating pediatric obesity
centers regarding their current practices.
Results: The work group developed consensus statements for use in the evaluation and treatment of lipids, liver enzymes, and
blood pressure abnormalities and PCOS in the child with overweight and obesity. The results of the FFFII survey illustrated the
variability in the approach for initial evaluation and treatment as well as pattern of referrals to subspecialists among programs.
Conclusions: The consensus statements presented in this article can be a useful tool for PCPs in the management and overall care
of children with overweight and obesity.
Introduction
C
hildhood overweight and obesity affect approxi-
mately one third of US children.1 Many of these
children have one or more obesity-related co-
morbidities, such as abnormal blood pressure, dyslipide-
mia, fatty liver disease, prediabetes, diabetes, polycystic
ovary syndrome (PCOS), obstructive sleep apnea, psy-
chosocial problems, and others. Children who are over-
weight or obese need to be routinely screened and, in many
cases, treated for these obesity-associated conditions.
Unfortunately, access to care for these comorbidities is
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inadequate because primary care pediatric providers (PCPs)
often are underequipped to deal with these complications.
Therefore, these children are frequently referred to multiple
pediatric subspecialists to address their comorbidities.2–5
Furthermore, many regions across the United States are ex-
periencing significant shortages of pediatric subspecialists,
resulting in limited access to timely evaluation and man-
agement by subspecialists.5–7 Considering that 12.5 million
US children are obese,8 new methods must be developed
to evaluate and manage the care of such a large number of
patients.
In 2009, the National Association of Children’s Hospitals
and Related Institutions (now known as the Children’s
Hospital Association) FOCUS on a Fitter Future II (FFFII)
assembled leaders from 25 leading pediatric obesity centers
from across the United States. From this collaboration, an
expert treatment committee work group was formed that
proceeded to meet every 4 months for the following 3 years.
As leaders of tertiary care childhood obesity clinics and
centers, the authors are frequently asked by primary care
colleagues what evaluation should be done for children with
childhood obesity and, beyond that, what then should be done
with the results. Various sources recommend initial labora-
tory evaluations for all children, but few recommendations
address how to manage and treat the results of abnormal
screening tests for obesity-related comorbidities in the pedi-
atric population. Furthermore, current screening recommen-
dations9,10 are primarily for children without overweight or
obesity and no literature covers how to specifically evaluate
children with obesity who are at greater risk for many
medical conditions, compared to their healthy weight peers.
No consensus statements or guidelines exist to provide a
framework for PCPs regarding what to do with abnormal
laboratory results in children who already are obese.
Given the lack of tools for the PCP that are easily ac-
cessible and user friendly and the shortage of subspecialty
care, the FFFII expert work group embarked on the devel-
opment of the clinical consensus statements presented in
this article. The clinical statements include a summary of
the screening, evaluation and initial treatment for obesity-
associated abnormalities of lipids, blood pressure, liver
enzymes, and PCOS. Consensus statements for other con-
ditions (e.g., sleep apnea) are also needed; however, they are
not presented in this article. The presented consensus state-
ments were based on the best available evidence at the time
of writing, including recommended guidelines from national
associations9–17 and advice from subspecialists from the
participating FFFII centers as well as nationally recog-
nized experts in the pertinent fields. The use of these
consensus statements can improve the care provided by
PCPs to children with overweight and obesity by facili-
tating appropriate evaluation, treatment, and potential
thresholds for referral to subspecialty care. Earlier iden-
tification of comorbidities and resultant prompt treat-
ment will decrease future health complications, lead to
healthcare cost savings, and increase quality of life for
these children.
Methods
FFFII surveyed the participating pediatric obesity centers
regarding their current evidence-informed approaches re-
garding the initial evaluation and treatment of obesity and its
comorbidities. The survey was designed by the treatment
committee work group of FFFII and completed by the leader
of each participating obesity center. In centers with some
clinical variation between different providers, the center’s
leader who completed the survey was asked to include only
those tests obtained by the majority of their providers. The
results of this survey illustrated the variability in the ap-
proach used for initial evaluation and pattern of referrals to
subspecialists among the participating obesity centers and
prompted the work group to develop user-friendly consen-
sus statements for use in the evaluation and treatment of
children with overweight and obesity.
These consensus statements were developed through:
 Committee discussions among the pediatric obesity ex-
perts from 25 pediatric obesity centers. All of these
centers met the criteria for stage III weight management
programs (comprehensive multidisciplinary teams, in-
cluding a dietician, physician, behavioralist, and exer-
cise physiologist or physical therapist), as described by
Barlow and colleagues.11
 A targeted review of the literature and review of the
existing guidelines from national associations9–17
 Consultation with subspecialists in nephrology, hepatol-
ogy, cardiology, endocrinology, pulmonology, gastroen-
terology, and gynecology for review of the consensus
statements and questions pertinent to their specific areas
of expertise. Nationally recognized experts were also
approached by members of the FFFII, as needed.
Each section of this article concludes with a flow dia-
gram developed by this group that summarizes their con-
sensus recommendations based on best available literature
and practice experience.
Extracts from the results of the survey administered to
the 25 pediatric obesity centers participating in FFFII are
shared in Figure 1 and throughout the article. These data
are presented to illustrate common practice and practice
variability, even among expert pediatric obesity centers,
but not as recommended best practice guidelines.
No institutional review board approval was required for
this study.
Results
Initial Assessment of the Child
with Overweight or Obesity
Multidisciplinary weight management programs evalu-
ate patients’ baseline metabolic measures and body com-
position for three primary purposes: (1) to evaluate
possible underlying diagnoses that may have contributed to
the development of obesity; (2) to identify physiological
sequelae of obesity; and (3) to provide data for monitor-
ing progress and response to treatment. Ultimately, this
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information helps providers adjust treatment plans and also
serves to enhance the motivation of patients and families in
view of present or impending serious health issues.
The 2007 American Medical Association (AMA) Expert
Committee recommendations on the prevention, assess-
ment, and treatment of child and adolescent overweight
and obesity include recommended laboratory testing that
should be performed when evaluating children with obesity
(Fig. 1a).11 Almost all members of FFFII obtain these re-
commended tests along with additional select tests ob-
tained to monitor patients’ progress (Fig. 1).
The results of the FFFII survey demonstrated signifi-
cant practice variability in the initial evaluation across the
participating pediatric weight management centers. Fig-
ure 1b describes the screening tests obtained by ‡ 80% of
the FFFII hospitals. Interestingly, despite the lack of clear
evidence for utility and that obtaining insulin is not sup-
ported by international recommendations,18 many pro-
grams continue to order fasting insulin levels. The reason
for obtaining insulin was not collected in the survey,
but anecdotally, FFFII members reported monitoring in-
tervention outcomes as part of a research protocol or
motivating behavior change in families as reasons for ob-
taining the test.
Other specific tests were ordered in response to history
or physical exam findings. Evaluations for PCOS or sleep
apnea, for example, were performed when relevant signs
and symptoms were noted (detailed PCOS evaluation is
described later in the article).
As a result of the high-risk population observed in such
referral centers and the need to monitor progress during
intensive treatment, most (50–< 80%) of the FFFII partici-
pating centers also obtained additional tests recommended
and supported by varying degrees of available evidence
(Fig. 1c). Screening for vitamin D deficiency is an example
of this variability and lack of consensus. Fifty-six percent of
centers routinely obtained vitamin D levels, whereas an-
other 9% obtained it only for high-risk and/or minority
patients. All hospitals followed the American Dietetic As-
sociation (now the Academy of Nutrition and Dietetics)
recommendations for supplementation, though the exact
treatment protocols also varied by program.19 Percentage
body fat was obtained by a majority of sites as a means of
monitoring progress, although participants acknowledged
Figure 1. Initial evaluation of the obese child: Current recommendation and practice variability among stage III pediatric obesity centers
participating in FFFII. *Obtained generally for research purposes or to monitor progress in specialized weight management programs.
LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine
transaminase; TSH, thyroid-stimulating hormone; free T4, free thyroxine. Color image is available online at www.liebertpub.com/chi
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that this is not a recommended practice for the general
practitioner. While acknowledging the inaccuracies often
noted with bioelectrical impedance analysis (BIA), most
centers measured percentage body fat using BIA. Seventy-
five percent of FFFII pediatric obesity centers reported
obtaining hemoglobin A1c (HbA1c). Although some de-
bate remains about the accuracy of HbA1c as a diabetes
screening test in the pediatric population,12,20 HbA1c was
adopted by the American Diabetes Association (ADA) as
an accepted tool to screen for glucose abnormalities in
adults in 2010.21 Only 4% of centers obtain oral glucose
tolerance tests (OGTTs) on all children referred to their
centers (Fig. 1d), but many centers considered OGTTs in
children with severe obesity or obesity with several risk
factors for diabetes. Details on the OGTT protocol, such as
number of glucose or insulin measurements performed,
were not collected in the survey. The recommended meth-
odology for OGTTs was published in 1998 by the World
Health Organization publication,22 which is also the meth-
odology currently supported by the ADA.23
Lipid Abnormalities
The Expert Committee recommendations for pediatric
obesity recommend including a fasting lipid panel for as-
sessment of youth with BMI ‡85th percentile, recognizing
that disordered lipid metabolism is one of the most common
early indicators of cardiovascular (CV) risk (CVR) in chil-
dren with overweight and obesity.11 These guidelines fo-
cus on low-density lipoprotein cholesterol (LDL-c) and
total cholesterol only. However, as many as 42.9% of obese
children will have combined dyslipidemia, which manifests
as elevated triglycerides and low high-density lipoprotein
cholesterol (HDL-c) with or without accompanying elevation
of LDL-c.24 Insulin resistance (IR) contributes to this com-
bined pattern, in which an increased burden of small LDL
particles may be masked by an unremarkable LDL-c level.25
Figure 2. Lipid management in children and adolescents with overweight or obesity (for nonobese children, refer to the American
Academy of Pediatrics guidelines).13 *Non-HDL-c = total cholesterol -HDL-c. {Risk factors described in Table 1. {Children with LDL-c
‡ 130 PLUS 0–1 risk factors fall between moderate and high risk. LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density
lipoprotein cholesterol. Color image is available online at www.liebertpub.com/chi
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Selective lipid screening with a fasting lipid profile for
children over 2 years of age has been recommended since
2008 for children with BMI ‡ 95th percentile.10,26 BMI
‡ 95th and 97th percentiles constitute moderate and high-
level risk factors that guide management in the 2011 Expert
Panel on Integrated Guidelines for Cardiovascular Health
and Risk Reduction in Children and Adolescents.10 These
guidelines also introduce non-HDL-cholesterol (calculated
by subtracting HDL-c from total cholesterol) as an accept-
able nonfasting screen for disordered lipid metabolism that
is followed, if abnormal, by a fasting sample to delineate the
specific nature of the dyslipidemia. All subsequent follow-
up labs for abnormal lipids should be fasting.
The management consensus statement presented in this
article is consistent with the most current CVR manage-
ment guidelines, with an emphasis on recognition and
management of the combined dyslipidemia associated with
obesity.10 In this consensus statement, obese/overweight
children are classified according to age and by risk based
on their lipid profile (Fig. 213). It is essential to note that
Figure 3. LDL-c management in children and adolescents with overweight or obesity with ‘‘high-risk’’ lipid profile (see Fig. 2). *Non-
HDL-c = total cholesterol -HDL-c. {Risk factors (see Table 1). {Statin therapy (see Table 2). LDL-c, low-density lipoprotein cholesterol;
HDL-c, high-density lipoprotein cholesterol. Color image is available online at www.liebertpub.com/chi
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weight management is the foundation of treatment for dy-
slipidemia for children with overweight/obesity of all ages.
Moderate and high-risk thresholds, despite optimized life-
style management that may justify adjunct nutraceutical and
pharmacological management, are detailed in Figures 3 and
427–29 and Tables 130,31 and 2. The LDL-c elevation that
accompanies obesity rarely exceeds 160 mg/dL, above which
primary genetic lipid disorders are more common. Obesity is
so prevalent, however, that a primary hypercholester-
olemia certainly can overlap with, and be exacerbated by,
excessive weight. If LDL-c exceeds 250 mg/dL, the likeli-
hood of concomitant familial hypercholesterolemia warrants
Figure 4. Triglyceride treatment (children ‡ 8 years) based on fasting triglyceride levels. *Before treatment with Lovaza: rule out alcohol use
by patient or family history of bleeding disorders; discontinue aspirin-containing products; and note that comparably concentrated prepa-
rations are increasingly available without prescription. LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol.
Color image is available online at www.liebertpub.com/chi
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consultation with a lipid specialist. Full CVR management
guidelines are found in the Expert Panel on Integrated
Guidelines for Cardiovascular Health and Risk Reduction in
Children and Adolescents, 2011.13
Abnormal Liver Enzymes
As the prevalence of childhood obesity continues to
increase, so has the incidence of nonalcoholic fatty liver
disease (NAFLD). Several studies have confirmed that
male gender and Asian and Mexican ethnicity are risk
factors for NAFLD, whereas African Americans seem to
be protected.32 NAFLD includes a range of disease se-
verity from simple steatosis to nonalcoholic steatohepati-
tis, which may progress to cirrhosis. Clinically, most
NAFLD is silent, although some patients may present with
abdominal pain. Metabolic syndrome is strongly correlated
with development and severity of NAFLD,33 and NAFLD
is also a risk factor independent of obesity in the devel-
opment of CV disease (CVD).34 Chronic overnutrition that
results in obesity creates an inflammatory cycle that pro-
motes IR and hepatic lipid deposition. Components of the
current American diet most responsible for the develop-
ment of NAFLD are saturated fats, particularly transfats,
fructose, and animal protein sources, and specifically
branched-chain amino acids, and alcohol.35
Table 1. Risk Factors for Cardiovascular
Disease
High-level risk factors and conditions
 Parent/grandparent/aunt/uncle with history of premature
cardiovascular disease (age at diagnosis < 55 years in males and
< 65 years in females), coronary atherosclerosis, peripheral
vascular disease, cerebrovascular disease, or early deaths
before 50 years of age of unknown cause in relatives
 BMI ‡ 97th percentile
 Diabetes mellitus, type 1 or 2
 Hypertension (blood pressure ‡ 99th percentile + 5 mm Hg,
requiring therapy)
 Current smoker
 Chronic renal disease
 History of solid organ kidney or heart transplant
 History of Kawasaki disease with current coronary aneurysms
Moderate-level risk factors and conditions
 BMI 95th–97th percentile
 Hypertension not requiring therapy
 HDL-c < 40 mg/dL




 History of Kawasaki disease with regressed coronary aneurysms
Consider as potential risk factors
 Prediabetes
 History of cancer30,31 or congenital heart disease
 Passive smoker
 Unknown family history
HDL-c, high-density lipoprotein cholesterol; HIV, human
immunodeficiency virus.
Table 2. Statin Therapy
 Document normal hepatic panel before initiating therapy.
 If a patient meeting eligibility for statins is a young woman of
reproductive age, it is essential to counsel to avoid pregnancy.
Statins should be withheld during pregnancy because of the
potential for teratogenicity for a developing fetus.
 Dosing:
– Start at lowest dose, usually at bedtime.
– If target LDL-c levels are not achieved, double the dose and
repeat lipid profile, creatine kinase (CK), and liver enzymes at
4 weeks. Continue stepped titration up to the maximum
recommended dose until the target LDL-c levels are achieved
(< 130, optimally < 110 mg/dL) or there is evidence of toxicity.
Repeat blood work at 4 weeks, 3 months, and then every
3–4 months for first year and every 6 months thereafter.
– Suggested titration:
 Pravastatin (Pravachol) 10‡ 20 mg
 Rosuvastatin (Crestor) 5‡ 10‡ 20 mg
 Atorvastatin (Lipitor) 10‡ 20 mg
– Note: Simvastatin (Zocor) is the least expensive, but most
lipophilic, and therefore passes readily across the blood–brain
barrier (BBB) and suppresses brain cholesterol synthesis. Plasma
cholesterol does not cross the BBB. Therefore, to avoid
interference with cholesterol needs for adolescent brain
development, more hydrophilic statins are favored.
– If LDL-c remains > 130 mg/dL on the maximum statin dose, can
add a bile acid sequestrant (Cholestyramine or Colestipol, 8 g
per day). Do not go higher in statin dose without consulting a
lipid specialist.
 Side effects:
– Instruct patient to immediately report side effects suggestive of
myopathy. If myopathy is present, the medication should be
stopped, and CK level and relation of symptoms to physical
activity should be assessed in 4–6 weeks. The patient should be
monitored for resolution of the myopathy and any associated
increases in CK. Consideration can be given to either an
alternate statin or restarting the same statin medication at half
the previous dose once symptoms and laboratory abnormalities
have resolved.
– Advise female patients about contraindication during pregnancy
and contraception if warranted. Advise about drug interactions
(cyclosporine, fibric acid derivatives, niacin, erythromycin,
azole antifungals, nefazodone, and HIV protease inhibitors).
LDL-c, low-density lipoprotein cholesterol; HIV, human
immunodeficiency virus.
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An Expert Committee (AMA, Health Resources and
Services Administration, and CDC) in 200711 recommended
assessment of liver enzymes in those children 10 years of
age with BMI ‡ 85th–94th percentile with risk factors and
in children 10 years of age with BMI ‡ 95th percentile.
Though alanine transaminase (ALT) and aspartate amino-
transferase (AST) levels are to be tested every 2 years and
coincide with diabetes screening recommendations, they
have low sensitivity and specificity for NAFLD. Normal
levels occur in patients found to have NAFLD on liver bi-
opsy and elevated levels are found in individuals with nor-
mal liver histology. The majority of the surveyed FFFII
programs checked liver enzymes at baseline starting at age 2
years. NAFLD can be strongly suspected based on clinical
parameters, liver enzymes (AST and ALT), and ultrasound
(US), but staging and grading currently require biopsy. With
worsening liver enzyme values, and before biopsy, other
forms of liver disease should be ruled out. Current treatment
for NAFLD is healthy diet and exercise. Recommendations
to limit or eliminate transfats, fructose, and alcohol exposure
and decrease animal protein intake are also suggested.35
The consensus statement presented for assessment of
NAFLD (Fig. 5) starts with the recommendation to measure
ALT in all children with obesity. The exact cut points for
referral and further evaluation are controversial because in-
sufficient evidence exists to guide decisions.36 This consen-
sus statement leans conservatively to assure that virtually all
those children with detectable NAFLD are followed closely
and referred early while also balancing access to gastroin-
testinal specialists. Further, upper limits of normal (ULNs)
vary in laboratories, and at times, these ULNs are very high.
For these reasons, the authors chose to use a number to guide
decisions in the consensus statement while acknowledging
that much of the evidence uses 2 times the ULN for the
typical cut point.11 Further evaluation to assess the presence
of other conditions, such as viral hepatitis and autoimmune or
metabolic abnormalities causing liver enzyme elevation, is
recommended (suggested tests are listed in Fig. 5).
In addition to the steps described in the consensus statement
(Fig. 5), the authors recommend talking with the receiving
subspecialist about preferences and additional potential lab-
oratory work that they might desire before the referral.
Hypertension
Normal blood pressure (BP) is defined as systolic and
diastolic BP (SBP/DBP) at less than the 90th percentile for
sex, age, and height,9 hypertension (HTN) as average SBP
or DBP ‡ 95th percentile on at least three separate occa-
sions, and pre-HTN is an SBP or DBP between the 90th
and < 95th percentile or BP exceeding 120/80 mm Hg in
adolescents.9 Obesity has been identified as a primary risk
factor for pre-HTN and HTN in childhood.9 As many as
13% of youth with obesity have elevated SBP and 9% have
elevated DBP.37 The presence of obesity increases the
likelihood that a hypertensive child will become a hyper-
tensive adult, thus compounding the risk for CVD these
children already face. Therefore, early identification and
timely treatment of HTN in youth with obesity is of par-
amount importance.
To develop the HTN consensus statement, the FFFII
members primarily used the Fourth Report on the Diagnosis,
Evaluation, and Treatment of High Blood Pressure in
Children and Adolescents, which reviewed the best avail-
able evidence for BP measurement and management
through 2003,9 and the Expert Panel on Integrated Guide-
lines for Cardiovascular Health and Risk Reduction in
Children and Adolescents: Summary Report, which re-
viewed this evidence through mid-200813 and stratified
recommendations by age. The resulting consensus statement
is shown in Figure 6. Cuff size and placement are critical to
the accurate measurement of BP, and cuff placement can be
more difficult in children and adolescents with obesity be-
cause larger cuff sizes are often required. In this population,
weight loss/management and dietary intervention will play a
role in all pathways of the HTN consensus statement with
additional assessment, treatment, and consultation depend-
ing on the diagnosis of HTN and its severity.
Polycystic Ovary Syndrome
PCOS is often described as the most common en-
docrinopathy in women of childbearing age, with reported
prevalence rates ranging from 5% to 10%.38–41 In 1990, the
National Institutes of Health consensus conference defined
PCOS as the combination of chronic anovulation or oligo-
menorrhea and clinical or biochemical signs of hyperan-
drogenism.42 Since then, two consensus groups have released
revised criteria that have incorporated polycystic ovaries
into the diagnostic criteria for PCOS.14,43 With the most
recent criteria proposed by the Androgen Excess Society,
nine different PCOS phenotypes can currently be identified,
characterized by hyperandrogenism (either clinical with
hirsutism and/or biochemical hyperandrogenemia) and ovar-
ian dysfunction (either oligoanovulation and/or polycystic
ovaries).44 In addition, the diagnosis of PCOS must exclude
other disorders of adrenal excess, such as nonclassic or late-
onset congenital adrenal hyperplasia, or disorders affecting
menstrual function, such as hyperprolactinemia.14
For adolescents, existing criteria for PCOS pose some
problems for diagnosis and management because some of
the symptoms or signs may be difficult to evaluate in this
age group.44,45 For instance, in the first 2 years following
menarche, oligomenorrhea is not uncommon because
menstrual cycles are frequently anovular.45 Therefore, both
adult PCOS guidelines14–16,46 and recommendations from
the Expert Committee on the prevention, assessment, and
treatment of child and adolescent overweight and obesity11
were used to inform the proposed management consensus
statements presented here for adolescent girls with obesity
(Figs. 7 and 8). In screening for PCOS, a primary goal is to
exclude and appropriately manage other medical conditions
that may cause irregular menstrual cycles and/or androgen
excess, such as hyperprolactinemia, thyroid dysfunction, or
nonclassic or late-onset congenital adrenal hyperplasia.
When performing laboratory tests, it is recommended to use
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a laboratory that will perform ultrasensitive pediatric assays
with pediatric reference ranges. Pelvic US is typically only
needed when either ovarian dysfunction (i.e., irregular men-
ses) or clinical hyperandrogenism (e.g., hirsutism) presents
alone with normal laboratory tests. In such cases, a diag-
nosis of PCOS can still be made if polycystic ovaries are
present on US.
Pharmacological management of irregular menses in
adolescent girls with PCOS is guided by the status of IR
and glucose tolerance.46–48 However, all obese adolescent
girls with PCOS will reduce their risk of CV complications
through intensive lifestyle modification and weight man-
agement as a complement to pharmacological therapy.15,17
Girls with normal glucose and normal insulin levels can be
Figure 5. Evaluation of abnormal liver enzymes inchildren with obesity. ALT, alanine transaminase; ANA, antinuclear antibody; Ab, antibody;
IgA, immunoglobulin A; GGT, gamma-glutamyl transpeptidase; GI, gastrointestinal. Color image is available online at www.liebertpub.com/chi
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treated initially with hormonal contraceptive pills. Estro-
gen suppresses luteinizing hormone (LH), and thus ovarian
androgen production, while also increasing sex hormone-
binding globulin production in the liver, and thus reducing
free testosterone. Some progestins, such as norgestrel and
levonorgestrel, may have higher androgenic activity and
should be avoided. In counseling families about hormone
treatment options, particularly in the nonsexually active
female, it may be important to refer to the medication as
‘‘hormonal therapy’’ marketed as oral contraceptives. This
Figure 6. Evaluation and treatment of hypertension in children with overweight or obesity. BUN, blood urea nitrogen; CBC, complete
blood count. Color image is available online at www.liebertpub.com/chi
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approach may decrease resistance to the treatment among
families, who may otherwise have concerns about placing
an adolescent on oral contraceptives. Adolescent girls with
overt IR (e.g., elevated insulin levels) and/or impaired glu-
cose homeostasis can be managed initially with metformin.
Patients have a high likelihood of ovulatory cycles while
taking metformin, and girls who are sexually active need to
be appropriately counseled. Data on reproductive outcomes
in adolescents are limited; however, modest weight loss of
5–10% of total body weight has also been shown to restore
ovulatory menstrual periods in obese adult women with
PCOS.49 Typically, treatment is continued for a minimum of
1 year followed by re-evaluation for spontaneous menses.
Hirsutism is a common complication of PCOS.50 For
adolescents with significant hirsutism, nonpharmacological
treatments may include shaving, waxing, and use of che-
mical depilatories and/or bleaching cream. Spironolactone,
50–100 mg twice-daily, is an effective primary therapy for
hirsutism. However, because of its teratogenicity, adoles-
cent patients using this medication should also be placed on
hormonal contraceptive therapy. Newer agents, such as
eflornithine, are also available and dermatology consultation
may also be considered.
Discussion
Because of the absence of guidelines for management of
pediatric obesity-related comorbidities specifically in obese
children, the FFFII participants generated a set of practical
consensus statements developed by reviewing best evi-
dence and guidelines from the literature as well as by
consensus from the participating pediatric obesity centers.
These statements focus on the clinical and laboratory
screening, interpretation of results, and treatment of the
most common comorbidities found in children and ado-
lescents who are overweight or obese.
These are recommended consensus statements for cli-
nicians to consider when developing treatment plans for
their pediatric patients with obesity. The unique circum-
stances of each patient must be considered. Practice vari-
ability is expected as a result of demographics, population
served, location, and resources available, among other
factors. This variability was clearly illustrated in the results
from the FFFII survey. The intention for the development
of the consensus statements is to improve the care of
children affected by obesity and its related comorbidities
and reduce the need for referrals to subspecialists, who are
Figure 7. Management of polycystic ovary syndrome (PCOS) in adolescents with obesity. DHEAS, dehydroepiandrosterone; LH, lutei-
nizing hormone; FSH, follicle-stimulating hormone; TSH, thyroid-stimulating hormone; free T4, free thyroxine; CAH, congenital adrenal
hyperplasia; MRI, magnetic resonance imaging. Color image is available online at www.liebertpub.com/chi
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scarce in many parts of the country. The availability of
these consensus statements should facilitate not only the
screening and diagnosis of the most common comorbid-
ities, but also lead to early initial management of these
conditions. By reducing referrals to subspecialists, earlier
diagnosis and treatment, these consensus statements can
improve the patient experience and can make care for
pediatric patients more cost-effective. Practice patterns
and access to subspecialists vary greatly by geography, so
these factors also need to be considered when creating a
treatment plan for a patient.
More research is needed to continue to improve the
treatment of childhood obesity-related comorbidities.
These consensus statements present a possible framework
from which the evaluations can be further studied and
adjusted based on the rapidly evolving field of pediatric
and adolescent obesity medicine.
Conclusions
The combination of a high number of children at risk for
obesity-related comorbidities, PCPs that have not enough
training or resources to deal with these problems, and the
shortage of pediatric subspecialists in the United States
creates a hazardous situation for these children. Obesity is
a relatively new disease, and comorbidities are just be-
ginning to be identified; therefore, one can only expect this
situation to deteriorate over time.
The consensus statements presented in this article may
help keep the management of these children in their
medical home and provide guidance to those sites that may
not have subspecialists available.
Further studies and large-scale clinical trials to assess
childhood obesity comorbidities are required to provide
more firm guidelines that are evidence based.
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